Thermo Fisher Scientific Inc. (NYSE:TMO) is Garrison Bradford & Associates Inc.’s 5th Largest Position

Garrison Bradford & Associates Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,800 shares of the medical research company’s stock after selling 1,500 shares during the period. Thermo Fisher Scientific makes up approximately 5.5% of Garrison Bradford & Associates Inc.’s portfolio, making the stock its 5th largest position. Garrison Bradford & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $4,020,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Hillsdale Investment Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 1,208.8% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 2,225 shares of the medical research company’s stock valued at $654,000 after purchasing an additional 2,055 shares in the last quarter. Clarius Group LLC raised its holdings in shares of Thermo Fisher Scientific by 13.6% in the 3rd quarter. Clarius Group LLC now owns 2,962 shares of the medical research company’s stock valued at $863,000 after purchasing an additional 355 shares in the last quarter. Cohen Lawrence B raised its holdings in shares of Thermo Fisher Scientific by 2.0% in the 2nd quarter. Cohen Lawrence B now owns 10,185 shares of the medical research company’s stock valued at $2,991,000 after purchasing an additional 195 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of Thermo Fisher Scientific by 66.7% in the 2nd quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after purchasing an additional 1,310 shares in the last quarter. Finally, Amica Retiree Medical Trust raised its holdings in shares of Thermo Fisher Scientific by 8.4% in the 2nd quarter. Amica Retiree Medical Trust now owns 3,184 shares of the medical research company’s stock valued at $935,000 after purchasing an additional 247 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

NYSE:TMO traded up $2.44 during midday trading on Tuesday, hitting $295.97. 754,521 shares of the company were exchanged, compared to its average volume of 1,265,393. The company has a fifty day simple moving average of $290.07 and a 200 day simple moving average of $283.92. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $306.00. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $118.15 billion, a PE ratio of 26.62, a price-to-earnings-growth ratio of 1.91 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.88 by $0.06. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. Thermo Fisher Scientific’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the business earned $2.62 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th will be paid a $0.19 dividend. The ex-dividend date of this dividend is Monday, December 16th. This represents a $0.76 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.

TMO has been the topic of several research analyst reports. Needham & Company LLC lifted their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $314.45.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now directly owns 283,502 shares in the company, valued at $84,483,596. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the transaction, the director now owns 28,592 shares in the company, valued at $7,803,614.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,833 shares of company stock worth $15,299,095. 0.45% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Index Funds

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.